



## **AbelZeta to Present at the Annual J.P. Morgan Healthcare Conference**

ROCKVILLE, MD, December 27, 2023 – AbelZeta Pharma, Inc. (“AbelZeta” or the “Company”), a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic products, today announced that Tony (Bizuo) Liu, Chairman and CEO, will present an update on the Company at the 42<sup>nd</sup> Annual J.P. Morgan Healthcare Conference on January 10, 2024.

Live Presentation: January 10, 2024  
Time: 8:00-8:25am PT  
Location: Mission Bay (32nd Floor) The Westin, San Francisco

### **About AbelZeta Pharma, Inc.**

AbelZeta is a global clinical-stage biopharmaceutical company with centers of excellence in Rockville, Maryland and Shanghai, China. AbelZeta is focusing on developing innovative and proprietary cell-based therapeutic products and is committed to ushering in bespoke treatments that harness the body's own immune system to fight against hematological malignancies and solid tumors, as well as inflammatory and immunological diseases. AbelZeta advances research and development in its own GMP facilities at its centers of excellence for early-stage clinical studies, with a pipeline comprised of CAR-T and TIL therapies.

### **Forward-Looking Statements**

Statements in this communication relating to plans, strategies, specific activities, and other statements that are not descriptions of historical facts are forward-looking statements. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include any risks detailed from time to time in the Company's reports. Such statements are based on the management's current beliefs and expectations and are subject to significant risks and uncertainties outside of management and the Company's control. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as otherwise required by law, the Company does not undertake any obligation, and expressly disclaims any obligation, to update, alter or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.

**Company Contact:**

Sarah Kelly

Director of Communications

AbelZeta Pharma, Inc.

+1 (240) 552 5870

[sarah.kelly@abelzeta.com](mailto:sarah.kelly@abelzeta.com)

[www.abelzeta.com](http://www.abelzeta.com)